What IFPMA does

IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) is a Geneva-headquartered, non-profit trade association founded in 1968 that represents the innovative pharmaceutical industry at the international level. The organization holds official relations with the United Nations and maintains working partnerships with multilateral bodies including WHO, WIPO, and PAHO. It serves a dual membership base of over 30 leading innovative pharmaceutical companies (including AstraZeneca, Roche, MSD, Novartis, and Pfizer) and more than 50 national and regional pharmaceutical industry associations worldwide, collectively representing over 90 entities. Its core mission is to champion pharmaceutical innovation, drive supportive policy, and convene stakeholders on global health priorities spanning pandemic preparedness, regulatory convergence, ethics, and access to medicines.

IFPMA's "products" are frameworks, codes, toolkits, and advocacy initiatives rather than commercial goods. Its portfolio includes the IFPMA Code of Practice (first established in 1981, the first industry ethics code of its kind for any sector), the Decision-Making Framework Toolkit ("Our Ethos in Action"), the six-body International Consensus Framework for Ethical Collaboration in Health, the WIPO-IFPMA-Interpat Intellectual Property Management Clinic (IPMC) for health tech SMEs, the Coalition for Access to NCD Medicines & Products, IQN Path for precision oncology, the Business Ethics for APEC SMEs Initiative, and advocacy campaigns including #AlwaysInnovating and #VaccinesForLife. It publishes position papers on topics ranging from regulatory reliance and AI in pharmaceutical manufacturing to international data flows and biotherapeutic products.

IFPMA generates revenue exclusively through recurring membership dues from member companies and national/regional associations — there is no external product sales motion. Its go-to-market approach is advocacy-led: member recruitment, multilateral engagement (UN, WHO, WIPO, G7/G20, APEC), and thought-leadership dissemination through publications, events, expert insights, and press briefings designed to influence global health policy. Leadership comprises a Director General (Dr. David Reddy) and a Vice Chair (Yaneth Giha of FIFARMA, the first Latin American in the role), with governance provided by member companies through council and committee structures.

Name

IFPMA

Legal name

International Federation of Pharmaceutical Manufacturers and Associations

Website

http://www.ifpma.org

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

IFPMA is a Geneva-based non-profit trade association, founded in 1968, that represents 30+ leading innovative pharmaceutical companies and 50+ national/regional associations. It advocates for the industry at the UN, WHO, and WIPO, publishing ethics codes, frameworks, and position papers on global health policy.

Ownership category

akta.pro rank

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership dues: IFPMA generates revenue through membership fees from pharmaceutical companies and national/regional pharmaceutical industry associations worldwide. Members include over 90 companies and associations representing the innovative pharmaceutical industry.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

IFPMA is a non-profit trade association representing the innovative pharmaceutical industry at the international level with official relations with the United Nations. It provides industry representation, an ethical compliance framework (the IFPMA Code of Practice), a Decision-Making Framework Toolkit, the International Consensus Framework for Ethical Collaboration in Health, and a portfolio of advocacy initiatives and partnerships covering access to medicines, regulatory convergence, IP management, and pandemic preparedness.

Product overview

IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) is a trade association representing the innovative pharmaceutical industry at the international level with official relations with the United Nations. Rather than offering a unified product platform, IFPMA provides a portfolio of initiatives, frameworks, and resources including the IFPMA Code of Practice (ethical compliance framework), the Decision-Making Framework Toolkit for ethical business decisions, the International Consensus Framework for Ethical Collaboration in Health, and various advocacy initiatives such as #AlwaysInnovating, #VaccinesForLife, and Global Health Progress. The organization also manages partnerships including the Intellectual Property Management Clinic (with WIPO and Interpat), the Coalition for Access to NCD Medicines & Products, IQN Path (precision oncology), and the Business Ethics for APEC SMEs Initiative. These offerings serve the association's mission to champion pharmaceutical innovation, drive supportive policy, and create sustainable solutions advancing global health.

Differentiator

Problem solved

Functional benefit

Brands

• #AlwaysInnovating: Campaign emphasizing that investing in innovative medicines and vaccines transforms health, drives economic growth, and improves health security
• #VaccinesForLife
• Global Health Progress

Products and services

• IFPMA Code of Practice A rules-based compliance framework for the pharmaceutical industry covering clinical research, fees for services, support for continuing medical education, and interactions with healthcare professionals, medical institutions and patient organizations. It sets ethical standards for the global pharmaceutical industry.
• Decision-Making Framework Toolkit (Our Ethos in Action) A five-phase Decision-Making Framework grounded in the IFPMA Ethos value system, designed to help companies balance business objectives and ethical considerations to meet patient needs and expectations of the medical community, regulators, and society. Includes customizable framework documents, background guides, presentation decks, and facilitation guides.
• International Consensus Framework for Ethical Collaboration in Health The only global platform of its kind convening six leading health stakeholder bodies (patients, nurses, doctors, pharmacists, hospitals, and the pharmaceutical industry) in support of high-quality patient care and ethical collaboration. Revised in 2024 to include principles on responsible use of health data and technology.
• Intellectual Property Management Clinic (IPMC) A global initiative led by WIPO in partnership with IFPMA and Interpat that supports health tech, MedTech, and biotech SMEs in building stronger intellectual property strategies through expert mentoring, training, and tailored IP roadmaps.

Quantifiable outcome

• 56 industry association codes from all 21 APEC economies implementing ethical standards aligned with APEC Mexico City Principles
• +4 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

13 partnerships are on record, tiered core and minor.

• WIPO (World Intellectual Property Organization)coreStrategic or Co-development Partner · 29 June 2026WIPO, IFPMA, and Interpat launched a partnership on June 29, 2026, at WIPO headquarters to support health tech, MedTech, and biotech startups and SMEs in strategic use of intellectual property. The MoU combines WIPO's established IP Management Clinic methodology (100+ workshops in 60 countries) with IFPMA's global pharmaceutical network. First phase will identify countries with growing health tech ecosystems for initial clinics.
• InterpatcoreStrategic or Co-development Partner · 29 June 2026Interpat contributes senior IP and patent counsel expertise to the IP Management Clinic partnership, supporting mentoring and technical guidance for SMEs. Interpat brings an IP professional community network to complement WIPO's methodology and IFPMA's pharmaceutical industry reach.
• Coalition for Access to NCD Medicines & ProductscoreStrategic or Co-development PartnerIFPMA is a founding member and serves as private sector representative on the Steering Committee of this multisectoral alliance addressing access to affordable medicines for non-communicable diseases. The Coalition includes governments, NGOs, academic institutions, civil society, and foundations working to address NCD medicines gaps in resource-limited settings.
• IQN PathcoreStrategic or Co-development PartnerIFPMA supports IQN Path, an international consortium working to improve quality and reach of biomarker testing for precision oncology. IFPMA helps strengthen global collaboration, support evidence-based solutions, elevate precision oncology in global health policy, and enable implementation efforts across LMICs.
• International Consensus Framework PartnerscoreStrategic or Co-development PartnerThe International Consensus Framework for Ethical Collaboration in Health is jointly supported by six leading bodies: IFPMA (pharmaceutical industry), IAPO (patients), International Council of Nurses, FIP (pharmacists), WMA (doctors), and IHF (hospitals). First established in 2014, revised in 2024 and adopted in 2025 with new principle on AI/health data.
• APEC (Asia-Pacific Economic Cooperation)coreStrategic or Co-development PartnerIFPMA serves as Industry Co-Chair of the Business Ethics for APEC SMEs Initiative biopharmaceutical sector program. This is the world's largest public-private partnership for ethical business practices in pharma, spanning all 21 APEC economies. The initiative disseminated APEC Mexico City Principles for ethical codes.
• LEEM (Les entreprises du médicament)minorOthersLEEM (French pharmaceutical industry association) collaborated with IFPMA and LIPA on a survey of eight multinational pharmaceutical companies regarding samples management requirements across 17 African countries.
• LIPA (Association des Industriels Pharmaceutiques en Afrique Francophone Subsaharienne)minorOthersLIPA collaborated with IFPMA and LEEM on surveying samples management requirements across African countries to inform efficient regulatory pathways.
• WHO (World Health Organization)coreStrategic or Co-development PartnerIFPMA maintains official relations with WHO and participates in multilateral health policy discussions. Engages through WHO Executive Board sessions, World Health Assemblies, and WHO initiatives including Advancing Clinical Trials Excellence in Africa (AVAREF).
• Africa Clinical Research Network (ACRN)minorOthersACRN works to improve Africa's capacity to attract and host clinical trials through better infrastructure and regulatory capacity building, aligned with IFPMA's goal to increase Africa's share of global clinical trials from 3% to 15% by 2035.
• WHO AVAREF (Advancing Clinical Trials Excellence in Africa)minorOthersWHO initiative working to improve clinical trial infrastructure and regulatory capacity in Africa, complementary to IFPMA's African Regulatory Conference activities and clinical trials expansion goals.
• G20 Health MinistersminorOthersIFPMA participates in G20 health policy discussions, advocating for recognition of pharmaceutical innovation as strategic investment. Industry leaders present positions on prevention budgets, economic growth, and healthcare value.
• nuvoteQminorOthersSouth African tech company developing digital platforms to showcase research sites to global clinical trial sponsors, supporting Africa's ability to attract clinical research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• PhRMA: Pharmaceutical Research and Manufacturers of America is the US national trade association for innovative pharma companies — the closest national analog to IFPMA. It represents similar member companies and runs parallel advocacy, ethics, and policy programs aimed at US regulators and Congress.
• EFPIA: European Federation of Pharmaceutical Industries and Associations represents the innovative pharma industry in Europe. It is IFPMA's main regional counterpart, with overlapping membership, parallel ethics codes, and shared policy engagement at EU institutions and WHO.

Broad incumbents

• BIO: Biotechnology Innovation Organization is the largest US biotech trade association. While broader in scope than IFPMA (including agriculture and industrial biotech), it competes for member mindshare among innovative pharma and runs overlapping advocacy on IP, pricing, and regulation.

Regional players

• JPMA: Japan Pharmaceutical Manufacturers Association represents innovative pharma companies in Japan. It is a member association of IFPMA and a parallel regional federation, with comparable codes, advocacy programs, and engagement with national regulators and WHO Western Pacific.
• FIFARMA: Latin American Federation of the Pharmaceutical Industry represents innovative pharma associations across Latin America. Its Executive Director currently serves as IFPMA Vice Chair, illustrating the structural and operational comparability between the two federations.

Emerging players

• IGBA: International Generic and Biosimilar Medicines Association represents the off-patent pharma industry. While focused on generics rather than innovators, it engages IFPMA's membership on overlapping IP, regulatory, and access topics at the same multilateral forums.
• Vaccines Europe: The vaccines-focused industry group within EFPIA. It addresses a subset of IFPMA's therapeutic scope and operates similar industry-advocacy and partnership models with WHO, GAVI, and CEPI, making it a useful partial-overlap comparator.
• Global Self-Care Federation: International association representing consumer healthcare and OTC manufacturers. It shares IFPMA's industry-association structure, membership-driven model, and WHO engagement on self-care and regulatory topics, but with a narrower therapeutic scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/IFPMA
• Facebookfacebook.com/IFPMA
• LinkedInlinkedin.com/company/ifpma

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IFPMA